CN110831604A - 用于肿瘤治疗或预防的药物组合物、方法及其用途 - Google Patents

用于肿瘤治疗或预防的药物组合物、方法及其用途 Download PDF

Info

Publication number
CN110831604A
CN110831604A CN201880044460.0A CN201880044460A CN110831604A CN 110831604 A CN110831604 A CN 110831604A CN 201880044460 A CN201880044460 A CN 201880044460A CN 110831604 A CN110831604 A CN 110831604A
Authority
CN
China
Prior art keywords
antibody
optionally substituted
tumor
seq
thionucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880044460.0A
Other languages
English (en)
Other versions
CN110831604B (zh
Inventor
宋宏梅
曾宏
钮晓达
王英
田强
肖代彪
蔡家强
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN110831604A publication Critical patent/CN110831604A/zh
Application granted granted Critical
Publication of CN110831604B publication Critical patent/CN110831604B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及包含4’‑硫代核苷磷酰胺衍生物或其药学可接受的盐、酯、水合物、溶剂化物、异构体、它们的任意晶型或消旋物、代谢物、或它们的混合物与其他药物组合的药物组合物，及其用于疾病治疗和/或预防的方法和用途。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201880044460.0A 2017-09-01 2018-08-24 用于肿瘤治疗或预防的药物组合物、方法及其用途 Active CN110831604B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017107813660 2017-09-01
CN201710781366 2017-09-01
PCT/CN2018/102242 WO2019042226A1 (zh) 2017-09-01 2018-08-24 用于肿瘤治疗或预防的药物组合物、方法及其用途

Publications (2)

Publication Number Publication Date
CN110831604A true CN110831604A (zh) 2020-02-21
CN110831604B CN110831604B (zh) 2023-05-02

Family

ID=65524908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880044460.0A Active CN110831604B (zh) 2017-09-01 2018-08-24 用于肿瘤治疗或预防的药物组合物、方法及其用途

Country Status (4)

Country Link
US (1) US11266674B2 (zh)
EP (1) EP3677267A4 (zh)
CN (1) CN110831604B (zh)
WO (1) WO2019042226A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218626B (zh) * 2019-12-31 2023-03-24 广州帝奇医药技术有限公司 一种持续释放组合物及其制备方法
CN115120744A (zh) * 2021-03-24 2022-09-30 四川大学 重组人内皮抑素腺病毒与抗pd-1抗体或抗pd-l1抗体在制备抗肿瘤药物中的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147058A (en) * 1996-04-09 2000-11-14 Yamasa Corporation 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
US20060142238A1 (en) * 2003-07-21 2006-06-29 Mcguigan Christopher Chemical compounds
WO2012045999A1 (en) * 2010-10-06 2012-04-12 Nucana Biomed Limited Phosphoramidite derivatives of gemcitabine for use in the treatment cancer
US20140364446A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2016068341A1 (ja) * 2014-10-31 2016-05-06 富士フイルム株式会社 チオヌクレオシド誘導体またはその塩および医薬組成物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
WO2016189055A1 (en) * 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
US20140315850A1 (en) 2011-07-19 2014-10-23 Nanjing Molecular Research, Inc. 2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof
US9012427B2 (en) * 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN107151269B (zh) 2016-03-04 2021-07-27 四川科伦博泰生物医药股份有限公司 一种pdl-1抗体、其药物组合物及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147058A (en) * 1996-04-09 2000-11-14 Yamasa Corporation 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
US20060142238A1 (en) * 2003-07-21 2006-06-29 Mcguigan Christopher Chemical compounds
WO2012045999A1 (en) * 2010-10-06 2012-04-12 Nucana Biomed Limited Phosphoramidite derivatives of gemcitabine for use in the treatment cancer
US20140364446A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2016068341A1 (ja) * 2014-10-31 2016-05-06 富士フイルム株式会社 チオヌクレオシド誘導体またはその塩および医薬組成物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
WO2016189055A1 (en) * 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer

Also Published As

Publication number Publication date
WO2019042226A1 (zh) 2019-03-07
EP3677267A1 (en) 2020-07-08
EP3677267A4 (en) 2021-06-02
CN110831604B (zh) 2023-05-02
US11266674B2 (en) 2022-03-08
US20200121707A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
JP2023039448A (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
CN111617078B (zh) 用于疾病治疗和/或预防的药物组合物、方法及其用途
CN112566661B (zh) 喹啉衍生物与抗体的药物组合
WO2020024932A1 (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
JP2022137089A (ja) 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
JP7352582B2 (ja) Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN110831604B (zh) 用于肿瘤治疗或预防的药物组合物、方法及其用途
TW202106716A (zh) 包含抗ｃｄ１２３免疫結合物之治療組合
CN113473989B (zh) Sumo活化酶抑制剂和检查点抑制剂的施用
JP2016515132A (ja) Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
CN112955188A (zh) 治疗神经内分泌肿瘤的方法
WO2023198060A1 (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
CN113747897A (zh) 喹啉衍生物与抗体联合治疗软组织肉瘤
WO2020044252A1 (en) Dosage regimes for anti-m-csf antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019088

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant